BW-34

BW-34 is an investigational small interfering RNA (siRNA) therapeutic being developed by Shanghai Argo Biopharmaceutical for the treatment of cardiovascular disease. Developed using the company's proprietary RNAi platform, BW-34 is designed to silence the expression of a specific, currently undisclosed gene target in the liver that is involved in the pathogenesis of cardiovascular conditions. The molecule likely utilizes a N-acetylgalactosamine (GalNAc) conjugation strategy to facilitate targeted delivery to hepatocytes via the asialoglycoprotein receptor (ASGPR). This approach aims to provide potent and durable knockdown of the target protein, potentially allowing for infrequent subcutaneous administration. BW-34 is part of a broader portfolio of RNAi candidates at Argo Biopharmaceutical targeting metabolic and cardiovascular diseases, some of which have been the subject of significant global licensing agreements.